Convergence Pharmaceuticals Ltd

CAMBRIDGE, England, November 21, 2011 - Phase I Single Dose Study Data Demonstrate Ideal Pharmacokinetic Profile and Excellent Safety and Tolerability Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.